ACIU

AC Immune SA

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$191.7M

Burn Rate (Qtr)

$20.6M

Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

ACI-24

Alzheimer's disease

Phase 2 12-mo interim analysis has been completed

Semorinemab

Alzheimer's disease (prodromal / mild)

Phase 2 did not meet primary endpoints

Semorinemab

Alzheimer's disease (moderate)

Phase 2 Remains Ongoing

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon